Jahaira Serrano Dominguez, MD
Pulmonary Disease · Arecibo, PRNPI 1245431451
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $72,075 of the $101,990 with a category attached, or 70.7%. AstraZeneca accounts for 87.0% of it on its own, with 19 other manufacturers making up the rest. Among pulmonary disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $290.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$89K
- Sanofi$6K
- Teva Pharmaceuticals USA, Inc.$4K
- GSK$1K
- Boehringer Ingelheim$814
- Genentech USA, Inc.$206
- plus $763 from 14 others
What the payments were for
- Consulting fees$12,49212%
- Speaking & faculty fees$72,07571%
- Travel & lodging$7,3487%
- Food & beverage$9,97010%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 145 | $88,759 |
| Sanofi | 54 | $5,988 |
| Teva Pharmaceuticals USA, Inc. | 11 | $3,981 |
| GSK | 70 | $1,480 |
| Boehringer Ingelheim | 31 | $814 |
| Genentech USA, Inc. | 10 | $206 |
| United Therapeutics Corporation | 4 | $128 |
| Merck | 5 | $99 |
| Medtronic | 1 | $82 |
| Sanofi-aventis U.S. LLC | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Insmed, Inc. | 2 | $60 |
| Mylan Specialty L.p. | 2 | $55 |
| Bayer | 2 | $37 |
| Shire North American Group Inc | 2 | $35 |
| Amgen | 1 | $34 |
| ANI Pharmaceuticals, Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Viatris Specialty LLC | 1 | $24 |
| Mylan LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$50,851
- TEZSPIRE$35,408
- DUPIXENT$4,877
- ProAir Digihaler$3,800
- AirDuo RespiClick$3,800
- ArmonAir Digihaler$3,800
How this compares
$101,990 in reported general payments places this provider in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 117 | $1,524,494 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 1,495 | $408,527 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 547 | $363,862 |
| Wixela InhubFluticasone Propion/Salmeterol | 1,629 | $344,078 |
| Breo ElliptaFluticasone/Vilanterol | 746 | $308,806 |
| Spiriva RespimatTiotropium Bromide | 512 | $281,427 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 449 | $220,905 |
| SymbicortBudesonide/Formoterol Fumarate | 903 | $214,552 |
| Dupixent PenDupilumab | 51 | $193,579 |
| TezspireTezepelumab-Ekko | 35 | $156,270 |
| FasenraBenralizumab | 24 | $138,369 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 207 | $135,251 |
| NucalaMepolizumab | 35 | $128,632 |
| Advair HfaFluticasone Propion/Salmeterol | 279 | $120,459 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,538 | $72,803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $814 | $2,034,2521,093 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta | $1,480 | $855,1761,497 claims |
| AstraZenecaSymbicort, Tezspire, Fasenra, Breztri Aerosphere | $88,759 | $644,4431,169 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $3,981 | $8,32427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Arecibo
- William Villanueva-BosqueArecibo$67K
- Alvaro Aranda RodriguezGuaynabo$725K
- Luis Garcia BarretoCoamo$393K
- Luis Nieves GarrasteguiRio Piedras$121K
- Domingo Chardon FelicianoPonce$45K
- Joel Nieves ScharonSan Juan$43K
- George FahedPonce$16K
- Luis Gerena MontanoSan Juan$15K
- Rafael Franjul JuliaoSan Juan$15K
- Roberto Martinez QuintanaSan Juan$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.